Quantcast
Home > Quotes > AGRX
AGRX

Agile Therapeutics, Inc. Common Stock (AGRX) Quote & Summary Data

$2.9
*  
0.04
1.4%
Get AGRX Alerts
*Delayed - data as of Apr. 19, 2018  -  Find a broker to begin trading AGRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AGRX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 2.91 / $ 2.8501
Share Volume
60,656
50 Day Avg. Daily Volume
110,622
Previous Close
$ 2.86
52 Week High / Low
$ 5.60 / $ 1.93
Market Cap
99,319,977
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
60,656
50 Day Avg. Daily Volume:
110,622

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.92

Trading Range

The current last sale of $2.90 is 50.26% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.91 $ 5.60
 Low: $ 2.8501 $ 1.93

Company Description (as filed with the SEC)

We are a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Twirla and our other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla┬«, also known as AG200-15, is a once-weekly prescription combination hormonal contraceptive patch that is at the end of Phase 3 clinical development. We completed the third of three Phase 3 clinical trials for Twirla in December 2016 and resubmitted our new drug application, or NDA, which was received by the U.S. Food and Drug Administration, or FDA, on June 26, 2017 and acknowledged as a complete response for FDA review on July 27, 2017. In connection with the NDA resubmission, we were assigned Prescription Drug User Fee Act, or PDUFA, goal date of December 26, 2017 by the FDA.  ... More ...  

Risk Grade

Where does AGRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.87
Open Date:
Apr. 19, 2018
Close Price:
$ 2.90
Close Date:
Apr. 19, 2018

Consensus Recommendation

Analyst Info